Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: a pilot study.
Fourteen patients with high-risk leukemia (six with relapsed AML, three with relapsed ALL, one with AML-M0, four with CML in myeloid blastic crisis) were treated with a combination chemotherapy of carboplatin (200-300 mg/m2/day) and cytosine arabinoside (100 mg/m2/day) by 24 h continuous infusion for 5-7 days. Five patients (35.7%) achieved complete remission including two patients complicated with myelofibrosis (one with AML-M0 and one with CML in myelo-megakaryocytic crisis). Thirteen patients had nausea and vomiting, five patients had severe, prolonged neutropenia for which it was necessary to administer granulocyte colony-stimulating factor and six patients had severe thrombocytopenia. We concluded that this regimen is effective for the treatment of high-risk leukemia.
Iwao
N
N
Department of Medicine, Jichi Medical School, Tochigi, Japan.
Yoshida
M
M
Hatake
K
K
Hoshino
Y
Y
Hagiwara
S
S
Tomizuka
H
H
Shimizu
R
R
Suzuki
T
T
Furukawa
Y
Y
Komatsu
N
N
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010865:Pilot Projects; D012074:Remission Induction; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced
D003561:Cytarabine; D016190:Carboplatin